#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

HIV infection

Recruiting

Registered drugNo placebo

Switching to Lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cabotegravir

Contact Research Centre

Plasma cell myeloma

Recruiting

InvestigationalNo placebo

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years

Contact Research Centre

Osteosarcoma

Recruiting

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carfilzomib

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

InvestigationalNo placebo

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Teclistamab

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Registered drugNo placebo

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Multiple sclerosis

Recruiting

InvestigationalNo placebo

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo

France

Participants:18–64 years
Substances:Ocrelizumab

Contact Research Centre

Colitis ulcerative

Recruiting

Investigational

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational

France

Participants:18–64 years · 65+ years

Contact Research Centre

Glomerulonephritis membranoproliferative+1

Recruiting

Registered drugNo placebo

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone

Contact Research Centre

Cardiac amyloidosis

Recruiting

InvestigationalNo placebo

Evaluation of [68Ga]Ga-FAPI-46 PET Imaging for Staging and Detecting Disease Progression in Patients with Transthyretin Cardiac Amyloidosis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Registered drugNo placebo

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Azacitidine

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.